A Phase II Study of CART-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Protocol No
ARCELLX-ARC-112A-CART-DDBCMA
Principal Investigator
Binod Dhakal
Phase
II
Summary
To find out more about an investigational drug, CART-ddBCMA (CAR-T) cells, in people with relapsed and refractory multiple myeloma. We want to find out whether the CAR-T cells reduce the symptoms of multiple myeloma, and whether they cause any problems.
Description
Phase II Study of CART-ddBCMA for the Treatment of Patients with R/R Multiple Myeloma
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL